mTOR and tyrosine kinase inhibitors may play an increasing role in the management of well-differentiated neuroendocrine tumors in the future. Peptide receptor radiotherapy is a new treatment ...

Using breast cancer patient-derived organoids and tumor ... Key changes include reduced activity of mTOR, a metabolic regulator, and structural shifts in E-cadherin, a molecule involved in cell ...

Periodically abstaining from food helps intestinal stem cells regenerate and heal from injuries—but also increases cancer ...

Targeted therapies for kidney cancer include anti-angiogenesis therapies, which stops the process of making new blood vessels; mTOR inhibitors, that target mTOR to slow kidney cancer growth; and HIF2a ...

Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 ...

Celcuity (CELC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Oliver McCammon ...

Using breast cancer patient-derived organoids and tumor ... Key changes include reduced activity of mTOR, a metabolic regulator, and structural shifts in E-cadherin, a molecule involved in cell ...